Research Article
Vitamin D Receptor Polymorphisms Predispose to Primary Biliary Cirrhosis and Severity of the Disease in Polish Population
Table 4
Clinical and laboratory data depending on analyzed polymorphisms.
(a) |
| ApaI (rs7975232) | | AA (TT) | aA (GT) | aa (GG) | P (AA versus Aa) | P (aa versus Aa) | P (aa versus AA) |
| Gender (F/M) | 36/4 | 67/13 | 20/3 | 0.4 | 0.9 | 0.7 | Cirrhosis at Lbx (N/Y) | 20/8 | 34/21 | 10/9 | 0.5 | 0.6 | 0.2 | Advanced fibrosis stage III/IV on histology (N/Y) | 15/11 | 28/27 | 8/10 | 0.6 | 0.3 | 0.5 | Age of diagnosis (years) | | | | 0.8 | 0.4 | 0.3 | AST (IU/mL) | | | | 0.4 | 0.4 | 0.2 | ALT (IU/mL) | | | | 0.2 | 0.9 | 0.3 | AP (IU/mL) | | | | 0.2 | 0.1 | 0.02 | GGT (IU/mL) | | | | 0.1 | 0.9 | 0.2 | Bilirubin (mg/dL) | | | | 0.9 | 0.3 | 0.4 | Albumin (g/dL) | | | | 0.1 | 0.9 | 0.2 | INR | | | | 0.1 | 0.1 | 0.9 | Cholesterol (mg/dL) | | | | 0.4 | 0.7 | 0.8 | TG (mg/dL) | | | | 0.2 | 0.8 | 0.5 | Sp100 Ab | 34/4 | 62/16 | 17/5 | 0.3 | 0.8 | 0.3 | Gp210 Ab | 31/7 | 67/11 | 21/1 | 0.6 | 0.3 | 0.2 | AMA (Y/N) | 31/9 | 68/12 | 19/4 | 0.3 | 0.7 | 0.7 |
|
|
(b) |
| BsmI (rs15444410) | | bb (GG) | bB (GA) | BB (AA) | P (bb versus Bb) | P (BB versus B) | P (bb versus BB) |
| Gender (F/M) | 40/8 | 66/9 | 17/3 | 0.6 | 0.7 | 0.9 | Cirrhosis at Lbx (N/Y) | 17/22 | 38/13 | 9/3 | 0.004 | 0.9 | 0.1 | Advanced fibrosis stage III/IV on histology (N/Y) | 15/23 | 30/20 | 6/5 | 0.1 | 0.7 | 0.5 | Age of diagnosis (years) | | | | 0.2 | 0.1 | 0.4 | AST (IU/mL) | | | | 0.05 | 0.9 | 0.2 | ALT (IU/mL) | | | | 0.2 | 0.8 | 0.3 | AP (IU/mL) | | | | 0.4 | 0.2 | 0.06 | GGT (IU/mL) | | | | 0.2 | 0.3 | 0.7 | Bilirubin (mg/dL) | | | | 0.5 | 0.5 | 0.8 | Albumin (g/dL) | | | | 0.4 | 0.6 | 0.9 | INR | | | | 0.2 | 0.4 | 0.9 | Cholesterol (mg/dL) | | | | 0.8 | 0.4 | 0.5 | TG (mg/dL) | | | | 0.6 | 0.2 | 0.4 | Sp100 Ab | 35/12 | 63/10 | 15/3 | 0.1 | 0.7 | 0.5 | Gp210 Ab | 41/6 | 62/11 | 16/2 | 0.8 | 0.9 | 0.9 | AMA (Y/N) | 40/8 | 63/12 | 15/5 | >0.9 | 0.3 | 0.5 |
|
|
(c) |
| TaqI (rs731236) | | TT (TT) | Tt (TC) | Tt (CC) | P (TT versus tT) | P (tt versus tT) | P (tt versus TT) |
| Gender (F/M) | 37/9 | 69/8 | 17/3 | 0.2 | 0.7 | 0.7 | Cirrhosis at Lbx (N/Y) | 15/9 | 40/13 | 9/3 | 0.3 | >0.9 | 0.7 | Advanced fibrosis Stage III/IV on histology (N/Y) | 13/23 | 32/20 | 6/5 | 0.03 | 0.7 | 0.3 | Age of diagnosis (years) | | | | 0.2 | 0.1 | 0.4 | AST (IU/mL) | | | | 0.03 | 0.9 | 0.2 | ALT (IU/mL) | | | | 0.2 | 0.9 | 0.3 | AP (IU/mL) | | | | 0.4 | 0.2 | 0.06 | GGT (IU/mL) | | | | 0.2 | 0.4 | 0.09 | Bilirubin (mg/dL) | | | | 0.9 | 0.6 | 0.6 | Albumin (g/dL) | | | | 0.4 | 0.6 | 0.9 | INR | | | | 0.6 | 0.5 | 0.7 | Cholesterol (mg/dL) | | | | 0.8 | 0.3 | 0.4 | TG (mg/dL) | | | | 0.6 | 0.2 | 0.4 | Sp100 Ab | 34/11 | 64/11 | 15/3 | 0.2 | 0.9 | 0.7 | Gp210 Ab | 39/6 | 64/11 | 16/2 | 0.9 | 0.9 | 0.9 | AMA (Y/N) | 40/6 | 62/15 | 16/4 | 0.5 | >0.9 | 0.5 |
|
|
Lbx: liver biopsy; AspAT: aspartate aminotransferase; AlAT: alanine aminotransferase; AP: alkaline phosphatase; GGT: gamma-glutamyl transferase; INR: international normalized ratio; TG: triglycerides, AMA: antimitochondrial antibodies.
|